The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
We believe that there is a strong rationale for the study of IDV/r 600/100 bid as a
boosted-PI combination that, in the presence of RMP, is able to produce a satisfactory PK
profile associated with adequate antiretroviral potency, tolerability and efficacy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration